Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.69 |
| ▸ | MAPK8 | P45983 | 16/20 | 0.69 |
| ▸ | MAPK9 | P45984 | 16/20 | 0.69 |
| ▸ | MAPK10 | P53779 | 16/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 14/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.60 |
| ▸ | YES1 | P07947 | 1/20 | 0.60 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629706 | 0.91 | MAPK1 (0.58) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL629071 | 0.89 | MAPK1 (0.56) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL630424 | 0.88 | MAPK1 (0.55) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL629332 | 0.87 | MAPK1 (0.54) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL629037 | 0.87 | MAPK1 (0.61) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL630346 | 0.86 | PIK3CA (0.53) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL630141 | 0.86 | MAPK1 (0.52) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL3637575 | 0.84 | PIK3CA (0.86) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL630406 | 0.84 | MAPK1 (0.60) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL629325 | 0.84 | MAPK1 (0.49) | PIK3CAMAPK8MAPK9MAPK10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394801-B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH (DE) | 2013-03-12 | — | — | US | claimed |
| EP-2419411-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | Æterna Zentaris GmbH (DE) | 2012-02-22 | — | — | EP | claimed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | claimed |
| US-8394801-B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8394801-B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8394801-B2 | Quinoxaline derivatives and their use for treating benign and malignant tumour disorders | AETERNA ZENTARIS GMBH (DE) | 2013-03-12 | — | — | US | disclosed |
| EP-2419411-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | Æterna Zentaris GmbH (DE) | 2012-02-22 | — | — | EP | disclosed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2010-10-21 | — | — | US | disclosed |
| WO-2010115719-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | ÆTERNA ZENTARIS GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115719-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | ÆTERNA ZENTARIS GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266538-A1 | QUINOXALINE DERIVATIVES AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOUR DISORDERS | NQO2, G6PD, GLS2 | PIK3CA 1981/4885MAPK8 2529/4885MAPK9 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.